G01N33/5306

Methods for processing nucleic acid molecules

The present disclosure provides methods, systems, and kits for processing nucleic acid molecules. A method may comprise providing a template nucleic acid fragment (e.g., within a cell, cell bead, or cell nucleus) within a partition (e.g., a droplet or well) and subjecting the template nucleic acid fragment to one or more processes including a barcoding process and a single primer extension or amplification process. The processed template nucleic acid fragment may then be recovered from the partition and subjected to further amplification to provide material for subsequent sequencing analysis. The methods provided herein may permit simultaneous processing and analysis of both DNA and RNA molecules originating from the same cell, cell bead, or cell nucleus.

METHODS FOR ENHANCING SPECIFICITY AND SENSITIVITY OF GROUP A STREPTOCOCCUS IMMUNOASSAY

The present disclosure provides methods and kits for detecting Group A Streptococcus in biological samples. More particularly, the present disclosure provides methods for enhancing the specificity and sensitivity of Group A Streptococcus immunoassays by including N-propionyl-D-glucosamine, 2-N-butanoyl-D-glucosamide, Bis-(2-(D-2-deoxy-glucosaminyl))-PEG3-amide, m-PEG4-glucosamine, m-PEG6-glucosamine, or m-PEG10-glucosamine. The methods and kits disclosed herein are thus useful for reliable and early diagnosis of streptococcal infections in a subject.

Selective optical detection of organic analytes in liquids

A method and a device for detection and quantification of various organic analytes in a liquid sample and an assay substrate for providing analyte measurements. The method is implemented by using specific interaction of organic analytes with selective binding sites immobilized on a multi-layer assay substrate with further detection of such interaction with a device based on inducing and recording the fluorescence of the substrate for bio-chemical, genetic and environmental analyses.

Methods of in situ antigen retrieval of a biological sample and imaging thereof

The invention relates to a device and method for in situ temperature-induced antigen retrieval of samples wherein all steps are performed under a pressure higher than the atmospheric pressure on a sample immobilized on a sample support which can be further subjected to staining and imaging on the same sample support, optionally by cycle multiplexing that enables imaging of various molecular targets through multi-molecular read-outs on the same sample in a rapid, highly sensitive and reliable manner.

Methods and systems for characterizing analytes from individual cells or cell populations

The present disclosure provides methods of processing or analyzing a sample. A method for processing a sample may comprise hybridizing a probe molecule to a target region of a nucleic acid molecule (e.g., a ribonucleic acid (RNA) molecule), barcoding the probe-nucleic acid molecule complex, and performing extension, denaturation, and amplification processes. A method for processing a sample may comprise hybridizing first and second probes to adjacent or non-adjacent target regions of a nucleic acid molecule (e.g., an RNA molecule), linking the first and second probes to provide a probe-linked nucleic acid molecule, and barcoding the probe-linked nucleic acid molecule. One or more processes of the methods described herein may be performed within a partition, such as a droplet or well. One or more processes of the methods described herein may be performed on a cell, such as a permeabilized cell.

METHOD OF MEASURING THE AFFINITY OF BIOMOLECULES
20170370927 · 2017-12-28 ·

The invention provides a method of measuring the affinity of first and second biomolecules in which a first biomolecule is tethered by a first tether portion having a first tether portion length and a second biomolecule is tethered by a second tether portion having a second tether portion length, the method comprising determining binding of adjacent first and second biomolecules to each other, varying at least one of the first and second tether lengths and determining binding of the first and second biomolecules. The invention also provides apparatus suitable for use in the method of the invention.

CANTILEVER SENSORS FOR MOLECULE DETECTION

The invention relates to a process for preparation of an unpassivated cantilever comprising the steps of: 1) providing a silicon cantilever sensor having two sides; 2) coating one side of the cantilever with at least a gold layer; and 3) functionalizing both sides of the cantilever with a self-assembled monolayer (SAM) of a probe molecule by incubating the cantilever in a solution having a concentration of the probe molecule of between 1 to 1000 μM.

The invention also relates to an unpassivated cantilever sensor comprising a silicon layer coated on one side with a coating comprising Au and being uncoated or unpassivated on the opposite side, wherein the Au coated surface comprises a self-assembled monolayer of a probe molecule and wherein the surface area occupied per probe molecule is in the range 0.4-1.5 nm.sup.2.

HIGH SENSITIVITY ANALYTE NETWORK DETECTION FLOW ASSAYS AND RELATED METHODS

Articles (e.g., lateral flow assays) and methods for the detection of an analyte are generally described. The assays may involve the use of a network which blocks or restricts flow in the assay, e.g., due to formation of an interconnect network or lattice.

COMPOSITIONS AND METHODS FOR CARRYING OUT ASSAY MEASUREMENTS
20220373554 · 2022-11-24 ·

The present disclosure provides compositions, reagents, kits, systems, system components, and methods for performing assays. More particularly, the disclosure relates to an assay composition for detecting Ituninescence, which comprises an alkyl diethanolamine, for example, N-butyldiethanolamnine (BDEA). In emodiments, the assay composition comprises 2-dihutylaminoethanol (BDAE),

METHOD FOR THE DETERMINATION OF ANTI-DRUG ANTIBODIES AGAINST AN EFFECTOR FUNCTION SUPPRESSED HUMAN OR HUMANIZED DRUG ANTIBODY

Herein is reported an anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody against an effector function suppressed human or humanized drug antibody in a sample comprising the incubation of a sample comprising mammalian blood serum with full length human Fcgamma receptor I or an Fc-region binding fragment thereof so that a complex between the anti-drug antibody against the effector function suppressed human or humanized drug antibody present in the sample and the human Fcgamma receptor I or the Fc-region binding fragment thereof forms, whereby the full length human Fcgamma receptor I or the Fc-region binding fragment thereof is conjugated to a detectable label, and the determination of the formed complex by the detectable label.